Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan To Cut Drug Prices in April

This article was originally published in PharmAsia News

Executive Summary

TOKYO - In the beginning of March, Japan's Ministry of Health, Labour and Welfare plans to release a full list of drugs that will be repriced starting in April. The average price cut is expected to be roughly 5.2 percent and includes top-selling prescription drugs
Advertisement

Related Content

Japan To Lower Price Of Eight Drugs From Takeda, Novartis, BMS And Chugai By 12-18 Percent
Novartis Gains Four New Drugs Under Japan NHI Reimbursement; Astellas, Takeda, BMS, GSK Make Gains
Japanese Pharmas Agree To Lower NHI Prices When Generic Uptake Is Slow
Japan’s Pharma Industry Proposes Plans To Reform Drug Pricing System
Japan Unlikely To Relax Dispensing Limits On New Drugs
Japan Sees Pharma Research as its Sunrise Sector, Alters Policy to Rev up R&D
USTR Objects to Japan’s Annual Drug Repricing Plan, Market Expansion Repricing
Daiichi Sankyo Forecasts Fall for Fiscal 2008 Due To Overseas Investments, R&D Growth
PharmAsia News Notable Notes: Japan’s Rising Health Care Funding Gap
Japanese Chugai Revises First Quarter Profit Outlook
Advertisement
UsernamePublicRestriction

Register

SC067653

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel